| Literature DB >> 33911896 |
Xin Liu1, Ziqiao Xu1, Yuting Wang1, Huiling Luo1, Donglei Zou1, Ziyuan Zhou2, Lixing Zhuang3.
Abstract
OBJECTIVE: This study aims to improve the reporting quality of randomized controlled trials (RCTs) by evaluating RCTs of acupuncture for low back pain (LBP) based on the CONSORT and STRICTA statements.Entities:
Keywords: CONSORT; STRICTA; acupuncture; low back pain; quality of reporting
Year: 2021 PMID: 33911896 PMCID: PMC8071706 DOI: 10.2147/JPR.S308006
Source DB: PubMed Journal: J Pain Res ISSN: 1178-7090 Impact factor: 3.133
Figure 1Flow chart of selection process. 31 RCTs were extracted for the final analysis.
General Characteristics of the Included 31 Studies
| No. | Included Trials | Publication Language | No. of Participants | Intervention | Course of Treatment | ||
|---|---|---|---|---|---|---|---|
| Trial | Control | Trial | Control | ||||
| 1 | Wasan 2010 | English | 21 | 19 | Acupuncture | Sham acupuncture | 21d |
| 2 | Chen 2010 | Chinese | 50 | 50 | Acupuncture | Transcutaneous electrical nerve stimulation | 5w |
| 3 | Su 2010 | Chinese | 30 | 30 | Acupuncture | Sham acupuncture | 1 session |
| 4 | Shankar 2011 | English | 30 | 30 | Electro-acupuncture | Valdecoxib | 3w |
| 5 | Hunter 2012 | English | 24 | 28 | Ear acupuncture + exercise | Exercise | 12w |
| 6 | Yun 2012 | English | 124 | 63 | Acupuncture | Usual care | 7w |
| 7 | Vas 2012 | English | 210 | 70 | Acupuncture | Conventional treatment | 4w |
| 8 | Cho 2013 | English | 65 | 65 | Acupuncture | Sham acupuncture | 6w |
| 9 | Shin 2013 | English | 29 | 29 | Motion style acupuncture | NSAIDs injection | 1 session |
| 10 | Wand 2013 | English | 25 | 25 | Sensory discrimination acupuncture | Usual acupuncture | 1 session |
| 11 | Weib 2013 | English | 79 | 77 | Acupuncture + standard rehabilitation programme | Standard rehabilitation programme | 21d |
| 12 | Hasegawa 2014 | English | 40 | 40 | Acupuncture | Sham acupuncture | 5 sessions |
| 13 | Seo 2017 | English | 27 | 27 | Bee venom acupuncture + Loxonin | Sham bee venom acupuncture + Loxonin | 3w |
| 14 | Kizhakkeveettil 2017 | English | 34 | 67 | Acupuncture | Spinal manipulative treatment/integrative care | 60d |
| 15 | Liu 2017 | English | 30 | 15 | 4/7 sessions acupuncture | 10 sessions acupuncture | 12w |
| 16 | Zhang 2017 | Chinese | 30 | 60 | Acupuncture | Sham acupuncture | 1 session |
| 17 | Wu 2017 | Chinese | 30 | 30 | Internal heating acupuncture | Warm acupuncture | 3w |
| 18 | Zheng 2018 | English | 63 | 27 | Electroacupuncture/sham acupuncture | Pain medication management (opioid medications) | 10w |
| 19 | Lee 2018 | English | 20 | 20 | Thread embedding acupuncture | Acupuncture | 8w |
| 20 | Heo 2018 | English | 18 | 21 | Electroacupuncture + usual care | Usual care | 4w |
| 21 | Liu 2018 | Chinese | 42 | 42 | Internal heating acupuncture | Warm acupuncture | 10d |
| 22 | Luo 2019 | English | 104 | 48 | Acupuncture | Usual care | 7w |
| 23 | Vas 2019 | English | 165 | 55 | Ear acupuncture + standard obstetric care | Standard obstetric care | 2w |
| 24 | Nicolian 2019 | English | 96 | 103 | Acupuncture | Standard care | 4w |
| 25 | Li 2019 | Chinese | 49 | 49 | Tiaoshen acupuncture | Usual acupuncture | 2w |
| 26 | Comachio 2020 | English | 33 | 33 | Electro-acupuncture | Manual acupuncture | 6w |
| 27 | Bishop 2020 | English | 69 | 41 | Acupuncture + standard care | Standard care | 6w |
| 28 | Sung 2020 | English | 19 | 19 | Thread embedding acupuncture + acupuncture | Acupuncture | 8w |
| 29 | Li 2020 | Chinese | 30 | 30 | Six-directions acupuncture | Usual acupuncture | 13d |
| 30 | Wang 2020 | Chinese | 34 | 34 | Acupuncture at tendon lesions | Usual acupuncture | 4w |
| 31 | Yang 2020 | Chinese | 99 | 99 | Floating acupuncture | Usual acupuncture | 10d |
Figure 2Year of publication. The blue bar is the number of RCTs published each year. The orange line is the median OQS with CONSORT statement of each year. The gray line is the median OQS with STRICTA statement of each year.
Details of OQS Assessed with CONSORT Statement (n=31)
| Items | Items No. | Items Details | No. of Positive RCTs | % | Cohen’s κ | 95% CI |
|---|---|---|---|---|---|---|
| 1.a | Identification as a randomized trial in the title | 29 | 93.55 | 0.78 | 0.38 to 1.00 | |
| 1.b | Structured summary of trial design, methods, results, and conclusions; for specific guidance see CONSORT for Abstracts | 27 | 87.10 | 0.87 | 0.62 to 1.00 | |
| Background and objectives | 2.a | Scientific background and explanation of rationale | 25 | 80.65 | 0.37 | 0.05 to 0.69 |
| 2.b | Specific objectives or hypotheses | 29 | 93.55 | 0.48 | 0 to 1.00 | |
| Trial design | 3 | Description of trial design including allocation ratio | 26 | 83.87 | 0.76 | 0.46 to 1.00 |
| Participants | 4.a | Eligibility criteria for participants | 31 | 100.00 | 0.89 | 0.69 to 1.00 |
| 4.b | Settings and locations where the data were collected | 21 | 67.74 | 0.50 | 0.19 to 0.81 | |
| Interventions | 5 | The interventions for each group with sufficient details to allow replication | 31 | 100.00 | 0.89 | 0.69 to 1.00 |
| Outcomes | 6 | Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed | 31 | 100.00 | 0.89 | 0.69 to 1.00 |
| Sample size | 7 | How sample size was determined | 17 | 54.84 | 0.81 | 0.61 to 1.00 |
| Randomization | ||||||
| Sequence generation | 8.a | Method used to generate the random allocation sequence | 16 | 51.61 | 0.49 | 0.18 to 0.79 |
| 8.b | Type of randomization; details of any restriction | 12 | 38.71 | 0.59 | 0.31 to 0.88 | |
| Allocation concealment | 9 | Mechanism used to implement the random allocation sequence, describing any steps taken to conceal the sequence until interventions were assigned | 12 | 38.71 | 0.52 | 0.21 to 0.83 |
| Implementation | 10 | Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions | 8 | 25.81 | 0.41 | 0.07 to 0.74 |
| Blinding | 11 | If done, who was blinded after assignment to interventions and how | 14 | 45.16 | 0.62 | 0.41 to 0.84 |
| Statistical methods | 12 | Statistical methods used to compare groups for primary and secondary outcomes | 28 | 90.32 | 0.64 | 0.18 to 1.00 |
| Participant flow | 13 | For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analyzed for the primary outcome | 23 | 74.19 | 0.67 | 0.39 to 0.95 |
| Implementation of intervention | ||||||
| Recruitment | 14 | Dates defining the periods of recruitment and follow-up | 18 | 58.06 | 0.74 | 0.49 to 0.98 |
| Baseline data | 15 | A table showing baseline demographic and clinical characteristics for each group | 26 | 83.87 | 0.67 | 0.34 to 1.00 |
| Numbers analyzed | 16 | For each group, number of participants included in each analysis and whether the analysis was by original assigned groups | 22 | 70.97 | 0.40 | 0.09 to 0.71 |
| Outcomes and estimation | 17 | For each primary and secondary outcome, results for each group, and the estimated effect size and its precision | 31 | 100.00 | 1.00 | – |
| Ancillary analyses | 18 | Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory | 23 | 74.19 | 0.67 | 0.37 to 0.96 |
| Harms | 19 | All important harms or unintended effects in each group; for specific guidance see CONSORT for Harms | 12 | 38.71 | 0.54 | 0.27 to 0.81 |
| Limitations | 20 | Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses | 20 | 64.52 | 0.45 | 0.04 to 0.85 |
| Generalizability | 21 | Generalizability (external validity, applicability) of the trial findings | 8 | 25.81 | 0.38 | 0.09 to 0.67 |
| Interpretation | 22 | Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence | 30 | 96.77 | 0.73 | 0.46 to 1.00 |
| Registration | 23 | Registration number and name of trial registry | 18 | 58.06 | 0.68 | 0.44 to 0.92 |
| Protocol | 24 | Where the full trial protocol can be accessed, if available | 6 | 19.35 | 0.89 | 0.64 to 1.00 |
| Funding | 25 | Sources of funding and other support; role of funders | 20 | 64.52 | 0.87 | 0.70 to 1.00 |
The Details of OQS Assessed with STRICTA Statement (n=31)
| Items | Item Details | No. of Positive RCTs | % | Cohen’s κ | 95% CI |
|---|---|---|---|---|---|
| 1. Acupuncture rationale | 1a) Style of acupuncture | 31 | 100.00 | 1.00 | – |
| 1b) Reasoning for treatment provided | 24 | 77.42 | 1.00 | – | |
| 1c) Extent to which treatment was varied | 4 | 12.90 | 0.43 | 0 to 0.89 | |
| 2. Details of needling | 2a) Number of needle insertions per subject per session | 23 | 74.19 | 0.83 | 0.61 to 1.00 |
| 2b) Names of points used | 23 | 74.19 | 0.67 | 0.39 to 0.95 | |
| 2c) Depth of insertion | 17 | 54.84 | 0.74 | 0.52 to 0.97 | |
| 2d) Response sought | 16 | 51.61 | 0.81 | 0.61 to 1.00 | |
| 2e) Needle stimulation | 19 | 61.29 | 0.49 | 0.23 to 0.75 | |
| 2f) Needle retention time | 30 | 96.77 | 0.65 | 0.02 to 1.00 | |
| 2g) Needle type | 24 | 77.42 | 0.74 | 0.46 to 1.00 | |
| 3. Treatment regimen | 3a) Number of treatment sessions | 28 | 90.32 | 0.52 | 0.04 to 0.99 |
| 3b) Frequency and duration of treatment sessions | 29 | 93.55 | 0.48 | 0 to 1.00 | |
| 4. Other components of treatment | 4a) Details of other interventions administered to the acupuncture group | 22 | 70.97 | 0.53 | 0.21 to 0.86 |
| 4b) Setting and context of treatment | 12 | 38.71 | 0.79 | 0.57 to 1.00 | |
| 5. Practitioner background | 5) Description of participating acupuncturists | 13 | 41.94 | 0.48 | 0.18 to 0.78 |
| 6. Control or comparator interventions | 6a) Rationale for the control or comparator in the context of the research question, with sources that justify this choice | 20 | 64.52 | 0.86 | 0.67 to 1.00 |
| 6b) Precise description of the control or comparator | 25 | 80.65 | 0.59 | 0.23 to 0.95 |